Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.57 |
| ▸ | BACE2 | Q9Y5Z0 | 7/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PPIA | P62937 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19731121 | 0.91 | BACE1 (0.54) | BACE1BACE2GRM5PPIA | |
| SCHEMBL14733559 | 0.85 | BACE1 (0.58) | BACE1BACE2GRM5LMNA | |
| SCHEMBL19725795 | 0.85 | BACE1 (0.59) | BACE1BACE2LMNA | |
| SCHEMBL19725864 | 0.85 | BACE1 (0.43) | BACE1BACE2FFAR4AGTR2LMNA | |
| SCHEMBL15366681 | 0.85 | BACE1 (0.55) | BACE1BACE2GRM5FFAR4 | |
| SCHEMBL15956460 | 0.84 | BACE1 (0.54) | BACE1BACE2GRM5LMNA | |
| SCHEMBL15938814 | 0.84 | BACE1 (0.54) | BACE1BACE2GRM5LMNA | |
| SCHEMBL19725796 | 0.83 | BACE1 (0.56) | BACE1BACE2GRM5LMNA | |
| SCHEMBL19731112 | 0.83 | BACE1 (0.42) | BACE1BACE2 | |
| SCHEMBL19731113 | 0.81 | BACE1 (0.49) | BACE1BACE2GRM5FFAR4AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3223820-B1 | 3-METHYL-2-IMINO-HEXAHYDRO-1H-PYRANO[3,4-D]PYRIMIDIN-4-ONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20170362248-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362248-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, APP, PSEN1 | BACE1 1/4885BACE2 4/4885GRM5 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.